21 September 2018
North Besada, MD
Drug Information Association
Invited speaker and panel discussant
To sufficiently define a clinical trial endpoint, both a relevant clinical outcome and an appropriate statistical test are needed. In addition, the interpretation (or clinical meaningfulness) of that data also should be specified. This session will describe the distinction between outcomes and endpoints, and discuss the evolution of endpoints throughout the drug development lifecycle. Time to deterioration endpoints in oncology clinical trials will be used as a case-study to illustrate endpoint positioning and interpretation.
Title of my presentation: Endpoint Selection and Positioning
Session agenda and speakers: